RAF inhibitors that evade paradoxical MAPK pathway activation (Q27702299)

21

object named as

Rafe Shellooe

0 references

Gaston Habets

6

object named as

Gaston Habets

0 references

Chao Zhang

1

object named as

Chao Zhang

0 references

author name string

Wayne Spevak

2

0 references

Ying Zhang

3

0 references

Elizabeth A Burton

4

0 references

Yan Ma

5

0 references

Jiazhong Zhang

7

0 references

Jack Lin

8

0 references

Todd Ewing

9

0 references

Bernice Matusow

10

0 references

Garson Tsang

11

0 references

Adhirai Marimuthu

12

0 references

Hanna Cho

13

0 references

Guoxian Wu

14

0 references

Weiru Wang

15

0 references

Daniel Fong

16

0 references

Hoa Nguyen

17

0 references

Songyuan Shi

18

0 references

Patrick Womack

19

0 references

Marika Nespi

20

0 references

Heidi Carias

22

0 references

Ben Powell

23

0 references

Emily Light

24

0 references

Laura Sanftner

25

0 references

Jason Walters

26

0 references

James Tsai

27

0 references

Brian L West

28

0 references

Gary Visor

29

0 references

Hamid Rezaei

30

0 references

Paul S Lin

31

0 references

Keith Nolop

32

0 references

Prabha N Ibrahim

33

0 references

Peter Hirth

Mutations of the BRAF gene in human cancer

34

0 references

language of work or name

English

0 references

publication date

22 October 2015

0 references

published in

Nature

0 references

volume

526

0 references

page(s)

583-6

0 references

issue

7574

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Progression of RAS-mutant leukemia during RAF inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Protein kinases: evolution of dynamic regulatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

The Rossmann Fourier autoindexing algorithm in MOSFLM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Overview of the CCP4 suite and current developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Molecular replacement with MOLREP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

PHENIX: a comprehensive Python-based system for macromolecular structure solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982

Refinement of macromolecular structures by the maximum-likelihood method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14982